Author

H. Rizos

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. A. Emran· 1 shared A. Ahn· 1 shared A. Rogiers· 1 shared A. W. Lund· 1 shared D. Gunatilake· 1 shared D. Lambrechts· 1 shared D. Pedri· 1 shared E. Leucci· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Emran

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor-resistant melanoma

F. Ahmed, H.-Y. Tseng, A. Ahn, D. Gunatilake, S. Alavi, M. Eccles, H. Rizos, S. Gallagher, J. TIFFEN, P. Hersey, A. A. Emran

This study shows that temozolomide combined with chloroquine can induce pyroptosis in BRAF/MAPK inhibitor-resistant melanoma by activating different inflammasomes.

bioRxiv · Aug 23, 2021Cancer Biology

A neural crest stem cell-like state drives nongenetic resistance to targeted therapy in melanoma

O. Marin-Bejar, A. Rogiers, M. Dewaele, J. Femel, P. Karras, J. Pozniak, G. Bervoets, N. Van Raemdonck, D. Pedri, T. Swings, J. Demeulemeester, S. Vander Borght, F. Bosisio, J. J. van den Oord, I. Vanden Bempt, , J.-C. Marine

This study identifies a neural crest stem cell-like state in melanoma minimal residual disease that drives nongenetic resistance to MAPK-targeted therapy and shows that targeting FAK/SRC signaling can delay relapse.

bioRxiv · Dec 15, 2020 · PreprintCancer Biology